Log in
NASDAQ:AKRX

Akorn Stock Forecast, Price & News

Notice: This company has been marked as potentially delisted and may not be actively trading.
Add
Compare
Today's Range N/A
50-Day Range
$0.09
MA: $0.19
$0.32
52-Week Range N/A
Volume1.19 million shs
Average Volume9.60 million shs
Market Capitalization$3.60 million
P/E RatioN/A
Dividend YieldN/A
Beta0.95
Akorn, Inc., a specialty generic pharmaceutical company, develops, manufactures, and markets generic and branded prescription pharmaceuticals, over-the-counter (OTC) consumer health products, and animal health pharmaceuticals in the United States and internationally. The company operates in two segments, Prescription Pharmaceuticals and Consumer Health. The Prescription Pharmaceuticals segment offers generic and branded prescription pharmaceuticals in various dosage forms, including sterile ophthalmics, injectables, and inhalants; and non-sterile oral liquids, topicals, nasal sprays, and otics. Its primary products include Akten, a topical ocular anesthetic gel; AzaSite, an antibiotic used to treat bacterial conjunctivitis; Cosopt, Cosopt PF, Betimol, and Zioptan, which are used in the treatment of glaucoma; and Xopenex inhalation solution used in the treatment or prevention of bronchospasm. The Consumer Health segment manufactures and markets OTC products for the treatment of dry eye under the TheraTears brand. It also markets other OTC consumer health products comprising Mag-Ox, a magnesium supplement; and the Diabetic Tussin line of cough and cold products. In addition, this segment offers a portfolio of animal health products, such as Anased and VetaKet veterinary sedatives; Tolazine and Yobine sedative reversing agents; and Butorphic, a pain reliever. Akorn, Inc. was founded in 1971 and is headquartered in Lake Forest, Illinois.
Akorn logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.0Community Rank: 2.7Dividend Strength: 0.0Insider Behavior: 0.8Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.43 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryPharmaceuticals
SectorMedical
Current SymbolNASDAQ:AKRX
CUSIP00972810
CIK3116
Phone847-279-6100
Employees2,227

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$682.43 million
Book Value$1.86 per share

Profitability

Net Income$-226,770,000.00

Miscellaneous

Market Cap$3.60 million
Next Earnings DateN/A
OptionableOptionable

Receive AKRX News and Ratings via Email

Sign-up to receive the latest news and ratings for AKRX and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Akorn (NASDAQ:AKRX) Frequently Asked Questions

Do Wall Street analysts recommend investors buy shares of Akorn?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Akorn in the last year. There are currently 1 hold rating for the stock, resulting in a consensus recommendation of "Hold."
View analyst ratings for Akorn
or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than Akorn?

Wall Street analysts have given Akorn a "Hold" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's winning trading ideas this year have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Akorn wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

How were Akorn's earnings last quarter?

Akorn, Inc. (NASDAQ:AKRX) issued its quarterly earnings data on Monday, May, 11th. The company reported $0.36 earnings per share (EPS) for the quarter, beating the Thomson Reuters' consensus estimate of ($0.09) by $0.45. The company had revenue of $204.69 million for the quarter, compared to analyst estimates of $168.90 million. Akorn had a negative net margin of 55.64% and a positive return on equity of 8.53%.
View Akorn's earnings history
.

What price target have analysts set for AKRX?

1 analysts have issued twelve-month price targets for Akorn's stock. Their forecasts range from $2.00 to $2.00. On average, they anticipate Akorn's share price to reach $2.00 in the next twelve months.
View analysts' price targets for Akorn
.

Who are some of Akorn's key competitors?

What other stocks do shareholders of Akorn own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Akorn investors own include (CELG), Integrated Device Technology (IDTI), Skechers U.S.A. (SKX), Rite Aid (RAD), Lannett (LCI), Bank of America (BAC), Quantenna Communications (QTNA), Ulta Beauty (ULTA), Paycom Software (PAYC) and Square (SQ).

Who are Akorn's key executives?

Akorn's management team includes the following people:
  • Mr. Duane A. Portwood, Exec. VP & CFO (Age 53)
  • Mr. Joseph Bonaccorsi, Exec. VP, Gen. Counsel & Sec. (Age 54)
  • Mr. Jonathan Kafer, Exec. VP & Chief Commercial Officer (Age 56)
  • Dr. Bruce Kutinsky, Consultant (Age 53)
  • Mr. Douglas S. Boothe, Pres, CEO & Direcor (Age 55)

What is Akorn's stock symbol?

Akorn trades on the NASDAQ under the ticker symbol "AKRX."

How big of a company is Akorn?

Akorn has a market capitalization of $0.00 and generates $682.43 million in revenue each year. The company earns $-226,770,000.00 in net income (profit) each year or ($0.34) on an earnings per share basis. Akorn employs 2,227 workers across the globe.

What is Akorn's official website?

The official website for Akorn is www.akorn.com.

How can I contact Akorn?

Akorn's mailing address is 1925 WEST FIELD COURT SUITE 300, LAKE FOREST IL, 60045. The company can be reached via phone at 847-279-6100 or via email at [email protected]

This page was last updated on 12/2/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.